Skip to main content
Clinical Trials/PACTR202301748714019
PACTR202301748714019
Not yet recruiting
Phase 2

Bifidobacterium infantis supplementation in early life to improve immunity in infants exposed to HIV: a randomized, placebo-controlled, double-blind trial

niversity of Cape Town0 sites200 target enrollmentJanuary 20, 2023

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Pregnancy and Childbirth
Sponsor
niversity of Cape Town
Enrollment
200
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 20, 2023
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversity of Cape Town

Eligibility Criteria

Inclusion Criteria

  • 1\) HIV uninfected at birth
  • 2\) Delivered at term
  • 3\) No pregnancy or delivery complications including birth asphyxia, seizures, sepsis, birth weight
  • 4\) \>2\.4kgs, and no known contraindications to probiotic supplementation

Exclusion Criteria

  • Mother: 1\) Complications during pregnancy and delivery such as gestational diabetes, obesity (BMI\> 35 prior to pregnancy), chorioamnionitis and eclampsia
  • 2\) Active TB or other infectious diseases
  • 3\) Administration of probiotics, prebiotics or immunoregulatory products
  • Infant: 1\) Hypoxic injury/ seizures/ sepsis/ Intrauterine growth retardation
  • 2\) Administration of probiotics, prebiotics or immunoregulatory products

Outcomes

Primary Outcomes

Not specified

Similar Trials